SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

The Cosmos network consists of many independent, parallel blockchains, called zones, each powered by classical Byzantine fault-tolerant (BFT) consensus protocols like Tendermint. Some zones act as hubs with respect to other zones, allowing many zones to interoperate through a shared hub. The architecture uses classic BFT and Proof-of-Stake algorithms, instead of Proof-of-Work. Cosmos can interoperate with multiple other applications and cryptocurrencies, something other blockchains can’t do well. By creating a new zone, you can plug any blockchain system into the Cosmos hub and pass tokens back and forth between those zones, without the need for an intermediary.  While the Cosmos Hub is a multi-asset distributed ledger, there is a special native token called the atom. ATOM have three use cases: as a spam-prevention mechanism, as staking tokens, and as a voting mechanism in governance.  As a spam prevention mechanism, ATOM are used to pay fees. The fee may be proportional to the amount of computation required by the transaction, similar to Ethereum’s concept of “gas”. Fee distribution is done in-protocol and a protocol specification is described here.  As staking tokens, ATOM can be “bonded” in order to earn block rewards. The economic security of the Cosmos Hub is a function of the amount of ATOM staked. The more ATOM that are collateralized, the more “skin” there is at stake and the higher the cost of attacking the network. Thus, the more ATOM there are bonded, the greater the economic security of the network.  Atom holders may govern the Cosmos Hub by voting on proposals with their staked ATOM.

Cosmos

Cosmos is generating significant buzz as the community actively debates its long-term viability, focusing on its potential as a central 'Internet of Blockchains' versus concerns over token inflation and ongoing network governance. Investors are heavily divided, balancing excitement around staking rewards and potential institutional adoption against frustrations over its recent market performance.

$RARI is an ERC-20 token that controls the RARI Foundation treasury and governs the Rarible protocol and RARI Chain. The token was issued in 2020 with a max. supply of 25 million $RARI.

Rarible

Rarible is trending as investors highlight its limited circulating supply, which is fueling speculation about potential price appreciation and scarcity-driven gains. Community members are actively debating the token's long-term utility in the NFT and DeFi sectors while expressing optimism that increased volume could trigger significant upward momentum.

XRP is a decentralized digital asset and the native token of the XRP Ledger, a Layer 1 blockchain designed for high-performance global payments. Its primary value proposition is offering a fast, cost-effective alternative to traditional banking systems by enabling near-instant cross-border settlements that finalize in three to five seconds. By serving as a neutral bridge asset between different fiat currencies, it helps financial institutions lower liquidity costs and eliminates the need for pre-funded accounts.  The network is unique because it utilizes a federated consensus protocol instead of energy-intensive mining or staking. This system achieves deterministic finality through a Unique Node List of trusted validators who must reach an eighty percent agreement threshold to permanently record transactions. This infrastructure supports a sustained throughput of 1,500 transactions per second and includes a built-in decentralized exchange that allows for the automated trading of any tokenized asset without intermediaries.  The project traces its origins back to 2004 with Ryan Fugger before being co-founded in its modern form by Jed McCaleb and Chris Larsen. The company, now known as Ripple, works with major financial institutions as partners and investors to build global payment solutions. To protect the network from spam, a small amount of XRP is burned during every transaction, and the token is further utilized by institutions as collateral to access traditional markets and manage digital asset infrastructure.  Institutional adoption of the asset reached a major milestone in November 2025 when the SEC approved the first wave of spot XRP ETFs. These products, offered by major issuers including Bitwise, Grayscale, 21Shares, Canary Capital, and Franklin Templeton, are now listed on prominent exchanges like the NYSE Arca, Nasdaq, and Cboe BZX. While Ripple remains a key contributor to the ecosystem, the underlying XRP Ledger continues to operate as an open-source and decentralized network.

Ripple

XRP is trending amid intense community debate over institutional integration rumors, specifically concerning SWIFT connectivity and the potential for regulatory clarity, while sentiment remains deeply polarized between retail holders anticipating utility-driven gains and skeptics dismissing the token as stagnant or manipulative.

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

Zebec Network is capturing attention as community members anticipate a potential Coinbase listing and potential partnerships following the completion of its token unlocks. Investors are actively discussing the protocol's real-time payroll utility and deflationary mechanics, with many maintaining a bullish outlook for its long-term adoption despite short-term price fluctuations.

Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of therapeutic candidates. Its product candidate, TP-03, is a novel therapeutic in Phase 2b/3 that is being developed for the treatment of blepharitis caused by the infestation of Demodex mites, which is referred to as Demodex blepharitis. It is also developing TP-04 for the potential treatment of Ocular Rosacea and TP-05 as an oral tablet for the potential prevention of Lyme disease. The company was founded by Bobak Azamian and D. Michael Ackermann in 2017 and is headquartered in Irvine, CA.

Tarsus Pharmaceuticals Inc

Tarsus Pharmaceuticals is generating significant market interest following a series of analyst price target increases and the recent FDA approval of its flagship drug, Xdemvy, for commercialization in the Greater China region. Investors are actively discussing the company's strong revenue growth trajectory, potential for further international expansion, and its attractiveness as a prospective M&A target due to its blockbuster potential in treating Demodex blepharitis.

KraneShares Trust - KraneShares CSI China Internet ETF

KraneShares CSI China Internet ETF

The KraneShares CSI China Internet ETF is drawing significant investor interest as market sentiment shifts toward undervalued Chinese tech giants, fueled by institutional accumulation and the unveiling of major AI breakthroughs from companies like Alibaba. Community discussion is heavily focused on potential stimulus measures and a technical breakout, with many traders emphasizing that long-term accumulation is finally translating into positive momentum despite ongoing geopolitical noise.

Surrozen, Inc. is a clinical stage biotechnology company, which engages in the business of discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. The company was founded by K. Christopher Garcia and Roeland Nusse on August 12, 2015 and is headquartered in South San Francisco, CA.

Surrozen Inc

Surrozen is actively trending as investors monitor potential buyout interest and upcoming pipeline milestones involving its Wnt-modulating ophthalmology assets, with the community closely tracking coordinated institutional buying from The Column Group. Retail sentiment remains focused on the company's potential to capitalize on the high-demand Wnt pathway sector, despite ongoing discussions regarding institutional share accumulation and the strategic rationale behind its recent capital raising and lease restructuring.

iShares Trust - iShares Biotechnology ETF

iShares Biotechnology ETF

The iShares Biotechnology ETF is seeing a surge in activity as investors weigh the potential for a new wave of M&A and regulatory shifts following recent high-profile acquisitions in the sector. Community sentiment is mixed, with some traders optimistic about sector-wide momentum and value in small-cap names, while others are cautioning about technical resistance levels and potential volatility as the broader market rotates.

Seres Therapeutics, Inc. engages in the development of biological drugs through microbiome therapeutics platform. Its product pipeline includes SER-109, SER-287, SER-301, and SER-401. The company was founded by Geoffrey von Maltzahn, David A. Berry, and Noubar B. Afeyan on October 18, 2010 and is headquartered in Cambridge, MA.

Seres Therapeutics Inc

Seres Therapeutics is experiencing heightened investor interest and volatile price action driven by persistent speculation regarding a potential buyout by its partner, Nestl. The community is actively debating the likelihood of a strategic acquisition and tracking high trading volume, with many participants viewing the company's recent operational restructuring and lean pipeline as signs that management is positioning the firm for a liquidity event.

Shell Plc engages in the business of producing oil and natural gas. It operates through the following segments: Integrated Gas, Upstream, Marketing, Chemicals and Products, Renewables and Energy Solutions, and Corporate. The Integrated Gas segment includes liquefied natural gas, and conversion of natural gas into gas-to-liquids fuels. The Upstream segment focuses on exploration and extraction of crude oil, natural gas, and natural gas liquids. The Marketing segment is involved in mobility, lubricants, and sectors and decarbonization businesses. The Chemicals and Products segment consists of chemicals manufacturing plants with marketing network and refineries, which turn crude oil and other feedstocks into a range of oil products. The Renewables and Energy Solutions segment provides renewable power generation, marketing, trading, and optimizing power and pipeline gas, as well as carbon credits and digitally enabled customer solutions. The Corporate segment covers non-operating activities supporting Shell such as holdings, treasury organization, self-insurance activities, and headquarters and central functions. The company was founded in February 1907 and is headquartered in London, the United Kingdom.

Shell Plc - ADR (Representing - Ordinary Shares)

Shell is currently trending due to a combination of favorable legal outcomes, specifically the overturning of a major Dutch climate ruling, and strategic positioning as a leader in global LNG trade. Investors are closely monitoring the company's capital discipline and share buyback programs, while community discussions focus on its expansion into high-margin deepwater assets and ongoing collaborations in carbon capture and hydrogen technologies.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 
